Carlo Rizzuto is a Managing Director at Versant Ventures where he invests across biopharma/biotech therapeutics at Seed through late-stage rounds (Seed, Series A–C, venture/early/late stage) in the U.S. (including Greater New York/East Coast/Northeastern U.S.) and Europe (including Basel). He has invested in companies like Century Therapeutics, Graphite Bio, Jnana Therapeutics, Repare, and Pandion Therapeutics. Before Versant, he was CEO of Highline Therapeutics and held roles at Novartis as Global Program Team Director and Assistant to the CEO (Pharmaceuticals) / Assistant to the CEO at Novartis International AG; he was previously an Associate Principal at McKinsey & Company and a Business Development Manager at engeneOS. Carlo holds degrees from Harvard University and the University of Virginia, and lives in New York.
Carlo Rizzuto, Managing Director @ Versant. Profile with intro opportunities and ranking information.
Not Yet Mapped
We've created a profile for Carlo Rizzuto from . Our ranking analysis and additional data will be available once our research is complete.
Rankings and detailed information coming soon
Network Strength
No ranking data available yet.
How to get an intro to Carlo
Map your path to Carlo instantly
Connect your network and Draftboard will automatically find and score the strongest paths to Carlo
That's it. Draftboard does the rest.
Rankings based on connection strength analysis - we ONLY show aggregate data, never specific connection data.